ライフサイエンスコーパス: SLNB

1 SLNB FS is highly effective in detecting the subgroup of

2 SLNB guided by a combination of radioisotope and blue dy

3 SLNB has replaced axillary lymph node dissection (ALND)

4 SLNB in patients undergoing surgery for breast cancer re

5 SLNB is the standard of care in surgical oncology of the

6 SLNB use was associated with clinicopathologic factors b

7 SLNB use was reported in 13.3% of patients with clinical

8 In the 106 SLNBs, which were found to be pathologically and clinica

9 Seventy-six patients underwent 2 SLNB procedures for a total of 775 intraoperative Tc-99

10 Of 33,639 SLNB patients (from 646 hospitals), 2916 (8.7%) had at l

11 rable breast cancer that were eligible for a SLNB from October 2002 to October 2010 were included in

12 ndred ninty-nine patients were accrued for a SLNB with an average age 57.1 +/- 12.8 (range 24-92).

13 ectively underwent 685 ARM procedures with a SLNB and/or ALND.

14 itals were divided into terciles of adjusted SLNB positivity rates.

15 dema after SLN biopsy (SLNB) alone and after SLNB followed by axillary lymph node dissection (SLNB/AL

16 However, even after SLNB alone, there remains a clinically relevant risk of

17 e physical and psychological morbidity after SLNB in the treatment of early breast cancer in a random

18 ates, and rates of regional recurrence after SLNB for melanoma using radiocolloid alone are acceptabl

19 atively new, the pattern of recurrence after SLNB is not yet clear.

20 When compared with SLNB/ALND, SLNB alone results in a significantly lower rate of lymp

21 When compared to SLNB/ALND, SLNB-alone results in a significantly lower rate of pati

22 Although SLNB use increased in both black and white patients with

23 Among 57 patients who had an SLNB, prepubertal patients had a higher percentage of se

24 Determine whether patients undergoing an SLNB required the addition of isosulfan blue dye to radi

25 High-volume units performed more BCS and SLNB than low-volume units (P < 0.001 and P < 0.001, res

26 need for axillary lymph node dissection, and SLNB is an accurate method of determining nodal status a

27 Tc99 sulfur colloid lymphoscintigraphy, and SLNB was performed with use of a conventional fixed gamm

28 ival rates or overall survival rates between SLNB and ALND groups but have shown significantly lower

29 proportion of sentinel lymph node biopsies (SLNB) performed by high-volume surgeons in invasive canc

30 Observations: Sentinel lymph node biopsy (SLNB) after NAC in patients presenting with clinically n

31 A) consisting of sentinel lymph node biopsy (SLNB) alone if sentinel lymph nodes (SLNs) were negative

32 ma rates in both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be b

33 performed before sentinel lymph node biopsy (SLNB) for breast cancer.

34 elines recommend sentinel lymph node biopsy (SLNB) for patients with clinical stage IB/II melanomas,

35 The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinically N0, oral cancer was teste

36 Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continually evolving.

37 d specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) examinations to detect metasta

38 Sentinel lymph node biopsy (SLNB) has become the gold standard for axillary staging.

39 al metastases by sentinel lymph node biopsy (SLNB) has been questioned.

40 e application of sentinel lymph node biopsy (SLNB) in the management of cutaneous squamous cell carci

41 Sentinel lymph node biopsy (SLNB) is a newly developed method of staging the axilla

42 Sentinel lymph node biopsy (SLNB) is an accurate, less invasive alternative to axill

43 Sentinel lymph node biopsy (SLNB) is being evaluated in breast cancer patients to im

44 T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the over

45 Sentinel lymph node biopsy (SLNB) is currently the standard of care for staging the

46 Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in pa

47 llowed by either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection.

48 uation by either sentinel lymph node biopsy (SLNB) or complete lymph node dissection (CLND) to all pa

49 er-than-expected sentinel lymph node biopsy (SLNB) positivity rates and whether hospitals with lower-

50 n validated that sentinel lymph node biopsy (SLNB) shows whether a patient's breast cancer or melanom

51 ts who underwent sentinel lymph node biopsy (SLNB) using radiocolloid guidance alone.

52 Sentinel lymph node biopsy (SLNB) was developed to replace axillary lymph node disse

53 , categorized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

54 database, using sentinel lymph node biopsy (SLNB), from 1992 to 2006, identified 109 patients with t

55 rwent subsequent sentinel lymph node biopsy (SLNB), which yielded negative findings in 32 (89%) patie

56 m prevalence of lymphedema after SLN biopsy (SLNB) alone and after SLNB followed by axillary lymph no

57 d thirty-six women who underwent SLN biopsy (SLNB) alone or SLNB followed by axillary lymph node diss

58 ); survival differences were not observed by SLNB positivity rates for stage II/III.

59 or T1 or T2 N0 oral squamous cell carcinoma, SLNB with step sectioning and immunohistochemistry, perf

60 followed by axillary lymph node dissection (SLNB/ALND) between June 1, 1999, and May 30, 2003, were

61 followed by axillary lymph node dissection (SLNB/ALND).

62 umerous case reports and case series examine SLNB findings in patients who were considered to have hi

63 year survival than those treated at expected SLNB positivity rate hospitals (90.0% vs 91.9%, P = 0.01

64 ge I patients treated at lower-than-expected SLNB positivity rate hospitals had worse 5-year survival

65 ospitals with lower- or higher-than-expected SLNB positivity rates have worse patient outcomes.

66 urgery at hospitals with lower-than-expected SLNB positivity rates was associated with decreased surv

67 ur colloid, nuclear imaging, narrow-exposure SLNB, and completion selective neck dissection.

68 illary recurrence rate was 0.2% and 1.4% for SLNB and ALND, respectively.

69 Guidelines for SLNB have focused on pathologic factors, but patient fac

70 er study is needed to define indications for SLNB in melanomas < 0.75 mm.

71 V is still insufficient to substitute it for SLNB for exclusion of axillary lymph node metastasis.

72 The false-negative rate for SLNB for melanoma is approximately 17%, for which failur

73 Objective lymphedema rates for SLNB and ALND were 0.8% and 6.5% respectively, with 26-m

74 , who would generally not be recommended for SLNB, had an LN positivity rate of 5.6% (95% CI, 3.3%-8.

75 rger, who would generally be recommended for SLNB, had an LN positivity rate of only 3.9% (95% CI, 2.

76 e differences in recurrence and survival for SLNB alone versus SLNB with completion ALND.

77 performed using the subareolar technique for SLNB in patients with operable breast cancer.

78 All patients underwent an FS SLNB.

79 Patients having SLNB alone were older than those having SLNB/ALND (56 v

80 ving SLNB alone were older than those having SLNB/ALND (56 v 52 years; P < .0001).

81 Hospital SLNB positivity rates may be a novel measure to confiden

82 Adjusted hospital SLNB positivity rates varied widely.

83 ith axillary lymph node dissection (ALND) if SLNB or PET was positive, or ALND alone if SLNs were not

84 Given its prognostic importance, SLNB should be considered in such patients, particularly

85 This racial disparity in SLNB use contributed to racial disparities in lymphedema

86 th Tc99-labeled radiocolloid localization in SLNB for melanoma.

87 ity of approximately 12 percentage points in SLNB use persisted through 2007.

88 by 863 surgeons, 56.4% underwent an initial SLNB, 37.2% initial axillary lymph node dissection, and

89 nt predictors of women undergoing an initial SLNB.

90 pital's SLNB positivity rate may reflect its SLNB proficiency for melanoma, but this has never been i

91 Hospital-level SLNB positivity rates were adjusted for patient- and tum

92 certainty regarding its use with mastectomy, SLNB or ALND is performed frequently.

93 For clinical stage IB/II melanoma, SLNB use was reported in 48.7% of patients.

94 Six of 175 patients with a negative SLNB developed a regional node recurrence as the first s

95 nce within the biopsied basin after negative SLNB's performed without isosulfan blue dye.

96 f sentinel lymph nodes (SLNs) were negative, SLNB with axillary lymph node dissection (ALND) if SLNB

97 of SLNB alone patients, compared with 16% of SLNB/ALND patients (P < .0001).

98 hatics were identified in 29.2% (138/472) of SLNB and 71.8% (153/213) of ALND.

99 measurements documented lymphedema in 5% of SLNB alone patients, compared with 16% of SLNB/ALND pati

100 b category that may warrant consideration of SLNB.

101 To assess the survival impact of SLNB in melanoma, the Multicenter Selective Lymphadenect

102 olds promise for reducing false negatives of SLNB for melanoma.

103 t was the negative-predictive value (NPV) of SLNB.

104 cancer from 2002 through 2007, the rates of SLNB remained lower in black than white patients during

105 The use of SLNB increased by year for both black and white patients

106 Racial disparities in the use of SLNB remain incompletely characterized, and their effect

107 6, 1.2%; 2012, 0.3%), with increasing use of SLNB.

108 st cancer expertise are less likely to offer SLNB to these patients, this practice pattern could lead

109 men who underwent SLN biopsy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/AL

110 ve breast cancer who underwent SLNB alone or SLNB/ALND.

111 allocated to undergo ALND (control group) or SLNB followed by ALND if subsequently found to be lymph

112 Surgeon and pathologist SLNB technical errors may lead to incorrect melanoma sta

113 s percentage varied by operation: PM 15%, PM SLNB 25%, LC 33%, LIH 15%, and IH 31%.

114 patients undergoing each operation: PM 5, PM SLNB 10, LC 15, LIH 15, and IH 15.

115 stectomy with sentinel lymph node biopsy (PM SLNB), laparoscopic cholecystectomy (LC), laparoscopic i

116 Positive SLNB findings by cSCC stage, quantified as the number an

117 The odds having a positive SLNB decreased by 13% each year with increasing age.

118 elationship between tumor stage and positive SLNB findings and to identify the optimal staging system

119 The AJCC criteria identifed positive SLNB findings in 0 of 9 T1 lesions (0%), 13 of 116 T2 le

120 Rates of positive SLNB findings in patients with T2b lesions were statisti

121 est that most cSCCs associated with positive SLNB findings occur in T2 lesions (in both staging syste

122 was reported in 3% of patients who received SLNB alone versus 27% of patients who received SLNB/ALND

123 NB alone versus 27% of patients who received SLNB/ALND (P < .0001), as compared with 5% and 16%, resp

124 A hospital's SLNB positivity rate may reflect its SLNB proficiency fo

125 Ninety-six SLNB procedures were done in 88 patients with breast can

126 However, these data support SLNB for MCC more than 1 cm in diameter.

127 ile) and higher-than-expected (high tercile) SLNB positivity rates were more likely to be low-volume

128 ve disease, clinical trials demonstrate that SLNB after NAC is accurate when 3 or more sentinel nodes

129 ease-free survival rates were better for the SLNB group than for the observation group, specifically

130 By using a 5% metastasis risk threshold, SLNB is indicated for melanomas >/= 0.75 mm, but further

131 AUS is a noninvasive alternative to SLNB for staging the axilla.

132 AUS may be an alternative to SLNB in these patients, where axillary surgery is no lon

133 When compared to SLNB/ALND, SLNB-alone results in a significantly lower r

134 not different between subjects randomized to SLNB with lymphadenectomy for nodal metastasis on biopsy

135 y less likely than white patients to undergo SLNB (odds ratio, 0.67; 95% CI, 0.60-0.75; P < .001).

136 ts were significantly more likely to undergo SLNB alone if they were older, had smaller tumors, or we

137 cifically, women were most likely to undergo SLNB if the operation was performed by high-volume surge

138 e IB/II melanoma were less likely to undergo SLNB if they were older than 75 years; had T1b tumors, n

139 gnated hospitals were most likely to undergo SLNB in adherence with national consensus guidelines.

140 cer are significantly more likely to undergo SLNB, highlighting the importance of receiving initial t

141 R, 1 [reference]), 8.8% in blacks undergoing SLNB (HR, 1.28; 95% CI, 1.02-1.60; P = .03), 12.2% in wh

142 cases had a higher likelihood of undergoing SLNB.

143 Stage IA-III melanoma patients undergoing SLNB were identified from the National Cancer Data Base

144 o December 2013 involved patients undergoing SLNB with or without ALND, or ALND alone.

145 ymphedema risk was 6.8% in whites undergoing SLNB (HR, 1 [reference]), 8.8% in blacks undergoing SLNB

146 8% underwent SLNB alone, and 79.2% underwent SLNB with completion ALND.

147 ent SLNB alone and 336 women (36%) underwent SLNB/ALND.

148 Of the 936 women, 600 women (64%) underwent SLNB alone and 336 women (36%) underwent SLNB/ALND.

149 Of 97,314 patients, 20.8% underwent SLNB alone, and 79.2% underwent SLNB with completion ALN

150 f negative US results subsequently underwent SLNB, which revealed lymph node metastasis in 12 (27%) p

151 ly node-negative breast cancer who underwent SLNB alone or SLNB/ALND.

152 rence or survival for patients who underwent SLNB alone versus completion ALND.

153 mes were examined for patients who underwent SLNB alone versus SLNB with completion ALND (median foll

154 with thin (</=1 mm) melanomas who underwent SLNB between 1992 and 2009 at Melanoma Institute Austral

155 pectively queried for patients who underwent SLNB for melanoma during the years 2005 through 2008.

156 ith primary cutaneous melanoma who underwent SLNB from 1991 through 1998 were identified from a prosp

157 zed primary cutaneous melanoma who underwent SLNB were identified.

158 tients with nonanogenital cSCC who underwent SLNB.

159 ive nodes has an accuracy similar to upfront SLNB and reduces the need for axillary lymph node dissec

160 oward better outcomes for completion ALND (v SLNB alone) after analysis was adjusted for differences

161 for patients who underwent SLNB alone versus SLNB with completion ALND (median follow-up, 63 months).

162 ecurrence and survival for SLNB alone versus SLNB with completion ALND.

163 ed that the rate of regional recurrence when SLNB is performed with radiocolloid alone would be compa

164 It is not known whether SLNB rates differ by surgeon expertise.

165 ity of choice for melanoma in patients whose SLNBs indicate no metastases.

166 This study examines factors associated with SLNB use for clinically node-negative melanoma.

167 Compared with SLNB alone, completion ALND does not appear to improve o

168 axillary lymph node dissection compared with SLNB prior to NAC.

169 When compared with SLNB/ALND, SLNB alone results in a significantly lower r

170 hospital type, geographic area) factors with SLNB use.

171 Lymphatic mapping with SLNB has become widely accepted in the management of pat

172 ave shown significantly lower morbidity with SLNB than with ALND.

173 an age 49.5 years (range: 14.4-85.0 years)], SLNB was positive for metastatic melanoma in 29 (6.7%) p